Phlow will manufacture epinephrine API in Virginia while Fresenius Kabi formulates and fills finished doses in existing US sites, creating a rare end-to-end domestic sterile injectable pathway.

Fresenius Medical Care faces ongoing market disinterest, as years of decent free cash flow generation have failed to drive meaningful market returns. Elevated U.S. mortality, a rough flu season, China ...

Michael Sen, CEO of Fresenius, talks to CNBC in Davos about the state of Europe’s healthcare sector. Sen argues that healthcare and pharmaceutical R&D are increasingly becoming part of the ...

The proposed aflibercept biosimilar is intended to treat ophthalmic disorders. This FDA submission follows the licensing agreement under which Fresenius Kabi will exclusively commercialize the ...

A leading U.S. senator is calling on federal regulators to share the results of an investigation into the dialysis industry, where critics say a "duopoly" has compromised the quality of critical, ...

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically ...

Organic Revenue Growth: 10% in Q3 2025, with contributions from all three operating segments. Operating Income Growth: Increased by 28%, with margin expansion from 9.9% to 11.7%. FME25+ Program ...

Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is ...

Fresenius’ operating company Fresenius Kabi reached a global settlement with Amgen concerning their denosumab biosimilars, allowing launch in the U.S. in mid-2025 and in Europe later in H2 of 2025, ...

Fresenius SE FRE0.90%increase; green up pointing triangle said it raised around 1.1 billion euros ($1.15 billion) after selling part of its Fresenius Medical Care FME 1.34%increase; green up pointing ...

(RTTNews) - Fresenius said that it plans to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share. Fresenius intends to sell approximately 10.5 ...

Fresenius SE raised close to €1.1 billion ($1.2 billion) in a sale of shares in Fresenius Medical Care AG as well as exchangeable bonds linked to the dialysis firm, as it looks to cut debt and ...